🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population

Recruitingn/aAges 30 Years - 60 YearsAllAin Shams University
NCT06755372 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic kidney disease (CKD) is a significant public health issue in Egypt, leading to end-stage renal disease (ESRD). ESRD patients often suffer from oral abnormalities due to the disease and medications. Periodontitis is linked to systemic diseases, including renal disease, with inflammation playing a key role. TLR4 genetic variations may influence susceptibility to CKD and periodontitis. This study investigates the association between TLR4 \[Gly/Thr (rs2149356)\] polymorphism and chronic periodontal disease in ESRD patients in Egypt.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Group I: Healthy Subjects with Periodontitis Inclusion Criteria: Age: 30 to 60 years Gender: Both male and female Diagnosed with Periodontitis stage II and/or stage III Systemically healthy, no history of systemic diseases Not on long-term medications Exclusion Criteria: Smokers Individuals with any systemic disease or long-term medication use Group II: ESRD Patients with Periodontitis Inclusion Criteria: Age: 30 to 60 years Gender: Both male and female Diagnosed with end-stage renal disease (ESRD) on regular hemodialysis Diagnosed with Periodontitis stage II and/or stage III Unrelated Egyptians from a similar socioeconomic status, residing in the same geographical area Underlying type 2 diabetes mellitus Exclusion Criteria: Individuals with kidney transplants Individuals with systemic diseases other than diabetes History of malignancy Smokers
💊

What it tests

  • Not listed
📍

Where

1 site
hemodialysis center at Benha University Hospital.
Al Fayyum, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy